Last reviewed · How we verify
K-757 and open-label sitagliptin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
K-757 and open-label sitagliptin (K-757 and open-label sitagliptin) — Kallyope Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| K-757 and open-label sitagliptin TARGET | K-757 and open-label sitagliptin | Kallyope Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- K-757 and open-label sitagliptin CI watch — RSS
- K-757 and open-label sitagliptin CI watch — Atom
- K-757 and open-label sitagliptin CI watch — JSON
- K-757 and open-label sitagliptin alone — RSS
Cite this brief
Drug Landscape (2026). K-757 and open-label sitagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/k-757-and-open-label-sitagliptin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab